source
- FDA unveils new rare disease framework to streamline evidence standards and speed therapiesThe FDA announced a new Rare Disease Framework Initiative aimed at standardizing how scientific evidence is evaluated for rare disease therapies. The framework seeks to apply consistent clinical t…
- Vanda halts Novartis-originated social anxiety drug after Phase 3 missVanda Pharmaceuticals announced it is suspending development of VQW-765, a social anxiety disorder candidate licensed from Novartis, after the drug failed to demonstrate a statistically significant…